Atrion (NASDAQ:ATRI – Get Rating) was upgraded by research analysts at StockNews.com from a “hold” rating to a “buy” rating in a research note issued to investors on Friday.
Atrion Stock Performance
NASDAQ:ATRI opened at $607.00 on Friday. The firm has a 50-day simple moving average of $600.05 and a 200-day simple moving average of $632.41. Atrion has a one year low of $542.10 and a one year high of $805.62. The firm has a market cap of $1.08 billion, a P/E ratio of 31.96 and a beta of 0.26.
Atrion (NASDAQ:ATRI – Get Rating) last issued its quarterly earnings data on Monday, August 8th. The medical instruments supplier reported $5.20 EPS for the quarter. The company had revenue of $48.88 million during the quarter. Atrion had a net margin of 19.12% and a return on equity of 14.03%.
Hedge Funds Weigh In On Atrion
A number of large investors have recently added to or reduced their stakes in ATRI. Boston Trust Walden Corp grew its position in shares of Atrion by 4.7% in the 1st quarter. Boston Trust Walden Corp now owns 43,209 shares of the medical instruments supplier’s stock worth $30,808,000 after buying an additional 1,957 shares during the last quarter. Crawford Investment Counsel Inc. grew its holdings in Atrion by 16.0% in the second quarter. Crawford Investment Counsel Inc. now owns 11,106 shares of the medical instruments supplier’s stock worth $6,984,000 after purchasing an additional 1,530 shares during the last quarter. Vestmark Advisory Solutions Inc. acquired a new position in shares of Atrion during the first quarter worth $664,000. NewEdge Wealth LLC purchased a new stake in shares of Atrion during the 1st quarter valued at $664,000. Finally, Millennium Management LLC boosted its position in shares of Atrion by 23.7% in the 2nd quarter. Millennium Management LLC now owns 4,694 shares of the medical instruments supplier’s stock worth $2,952,000 after purchasing an additional 900 shares in the last quarter. 65.68% of the stock is currently owned by institutional investors.
About Atrion
Atrion Corporation, together with its subsidiaries, develops, manufactures, and sells products for fluid delivery, cardiovascular, and ophthalmology applications in the United States, Canada, Europe, and internationally. Its fluid delivery products include valves that fill, hold, and release controlled amounts of fluids or gasses for use in various intubation, intravenous, catheter, and other applications in the anesthesia and oncology fields, as well as promote infection control in hospital and home healthcare environments.